MILESTONE PHARMACEUTICALS IN (MIST) Stock Price, Forecast & Analysis

NASDAQ:MIST • CA59935V1076

1.72 USD
-0.1 (-5.49%)
At close: Feb 12, 2026
1.7102 USD
-0.01 (-0.57%)
After Hours: 2/12/2026, 8:01:15 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News

MIST Key Statistics, Chart & Performance

Key Statistics
Market Cap146.49M
Revenue(TTM)N/A
Net Income(TTM)-58.01M
Shares85.17M
Float78.88M
52 Week High3.06
52 Week Low0.63
Yearly DividendN/A
Dividend Yield0%
EPS(TTM)-0.83
PEN/A
Fwd PEN/A
Earnings (Next)03-11
IPO2019-05-09
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals
MIST short term performance overview.The bars show the price performance of MIST in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -5 -10 -15

MIST long term performance overview.The bars show the price performance of MIST in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 -10 -20 -30 -40

The current stock price of MIST is 1.72 USD. In the past month the price decreased by -15.27%. In the past year, price decreased by -24.23%.

MILESTONE PHARMACEUTICALS IN / MIST Daily stock chart

MIST Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating
MIST Full Technical Analysis Report

MIST Fundamental Analysis

ChartMill assigns a fundamental rating of 1 / 10 to MIST. MIST has a bad profitability rating. Also its financial health evaluation is rather negative.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
MIST Full Fundamental Analysis Report

MIST Financial Highlights

Over the last trailing twelve months MIST reported a non-GAAP Earnings per Share(EPS) of -0.83. The EPS decreased by -2.35% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -66.11%
ROE -282.97%
Debt/Equity 2.74
Chartmill High Growth Momentum
EPS Q2Q%14.29%
Sales Q2Q%N/A
EPS 1Y (TTM)-2.35%
Revenue 1Y (TTM)-100%
MIST financials

MIST Forecast & Estimates

11 analysts have analysed MIST and the average price target is 6.73 USD. This implies a price increase of 291.4% is expected in the next year compared to the current price of 1.72.


Analysts
Analysts80
Price Target6.73 (291.28%)
EPS Next Y-6%
Revenue Next YearN/A
MIST Analyst EstimatesMIST Analyst Ratings

MIST Ownership

Ownership
Inst Owners45.72%
Ins Owners3.57%
Short Float %11.9%
Short Ratio1.6
MIST Ownership

MIST Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
SymbolCompany NameTechnical RatingFundamental RatingFPEMarket Cap
LLY ELI LILLY & CO30.93959.759B
JNJ JOHNSON & JOHNSON20.99580.304B
MRK MERCK & CO. INC.22.04296.13B
PFE PFIZER INC9.15157.665B
BMY BRISTOL-MYERS SQUIBB CO9.84122.002B
ZTS ZOETIS INC18.2956.704B
RPRX ROYALTY PHARMA PLC- CL A8.6425.543B
VTRS VIATRIS INC6.2418.578B
ELAN ELANCO ANIMAL HEALTH INC23.7112.774B
AXSM AXSOME THERAPEUTICS INC223.389.387B

Related stock screener links

View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges

About MIST

Company Profile

MIST logo image Milestone Pharmaceuticals, Inc. engages in the development and commercialization of cardiovascular medicines. The company is headquartered in Montreal, Quebec and currently employs 33 full-time employees. The company went IPO on 2019-05-09. The firm is focused on the development and commercialization of cardiovascular medicines. Its lead product candidate, etripamil, is a potent rapid-onset calcium channel blocker that the Company designed and is developing as a rapid-onset nasal spray to be administered by patients. The firm is also focused on developing etripamil to treat paroxysmal supraventricular tachycardia, atrial fibrillation, and other cardiovascular indications.

Company Info

MILESTONE PHARMACEUTICALS IN

420-1111 boul. Dr.-Frederik-Philips

MONTREAL QUEBEC H4M 2X6 CA

CEO: Joseph Oliveto

Employees: 33

MIST Company Website

MIST Investor Relations

Phone: 15143360444

MILESTONE PHARMACEUTICALS IN / MIST FAQ

What does MILESTONE PHARMACEUTICALS IN do?

Milestone Pharmaceuticals, Inc. engages in the development and commercialization of cardiovascular medicines. The company is headquartered in Montreal, Quebec and currently employs 33 full-time employees. The company went IPO on 2019-05-09. The firm is focused on the development and commercialization of cardiovascular medicines. Its lead product candidate, etripamil, is a potent rapid-onset calcium channel blocker that the Company designed and is developing as a rapid-onset nasal spray to be administered by patients. The firm is also focused on developing etripamil to treat paroxysmal supraventricular tachycardia, atrial fibrillation, and other cardiovascular indications.


Can you provide the latest stock price for MILESTONE PHARMACEUTICALS IN?

The current stock price of MIST is 1.72 USD. The price decreased by -5.49% in the last trading session.


Does MIST stock pay dividends?

MIST does not pay a dividend.


What is the ChartMill rating of MILESTONE PHARMACEUTICALS IN stock?

MIST has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.


Can you provide the PE ratio for MIST stock?

MILESTONE PHARMACEUTICALS IN (MIST) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.83).


Who owns MILESTONE PHARMACEUTICALS IN?

You can find the ownership structure of MILESTONE PHARMACEUTICALS IN (MIST) on the Ownership tab.